Aldeyra Therapeutics, Inc. (ALDX) stock
Close on Nov 13, 2026Market cap $38.84MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $38.84M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.10
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$19.13M
- EPS, diluted
- -$0.32
- Book value per share
- $0.58
- Diluted shares
- 60M
Trading
- Previous close
- $0.63
- Open
- $0.61
- Day's range
- $0.59 – $0.66
- Volume
- 764,019
- Average volume (20 days)
- 815,088
- Beta (5 years)
- 2.02
- 52-week range
- $0.53 – $5.93
- RSI (14 days)
- 38.2
- Volatility (1 year)
- 118.3%
- Relative volume
- 0.68×
- WACC
- 15.2%
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | ALDX | S&P 500 | Difference | ALDX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -28.5% | -3.0% | −25.4 pts | ||
| 3 months | -55.3% | -2.8% | −52.5 pts | ||
| Year to date | -87.6% | +11.5% | −99.1 pts | ||
| 1 year | -87.2% | +13.5% | −100.6 pts | ||
| 3 years | -73.8% | +77.7% | −151.5 pts | -36.0% | +21.1% |
| 5 years | -92.7% | +72.6% | −165.3 pts | -40.8% | +11.5% |
| 10 years | -89.8% | +308.2% | −398.0 pts | -20.4% | +15.1% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Aldeyra Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About Aldeyra Therapeutics
Pharmaceutical Preparations
Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing therapies for immune-mediated diseases. Its approach centers on modulating protein systems through small molecules designed to bind, degrade, and deplete reactive aldehyde species (RASP), targeting multiple inflammatory pathways simultaneously. The company’s pipeline includes late-stage investigational candidates such as reproxalap, an ophthalmic solution evaluated for dry eye disease and allergic conjunctivitis, and ADX-2191, an intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa. In addition, it develops product candidates like ADX-248 and ADX-246 for systemic, dermatologic, and retinal conditions.
Company profile, executives and historyAldeyra Therapeutics stock: common questions
What is Aldeyra Therapeutics's stock price?
ALDX closed at $0.64 on Nov 13, 2026, up 2.17% on the day. Over the past 52 weeks it traded between $0.53 and $5.93.
What is Aldeyra Therapeutics's market cap?
Aldeyra Therapeutics was worth $38.84M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is ALDX's P/E ratio?
Aldeyra Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.32), so it has no meaningful P/E ratio.
Does Aldeyra Therapeutics pay a dividend?
No. Aldeyra Therapeutics has not paid a cash dividend over the last twelve months.
How has ALDX stock performed over the past year?
Including dividends, ALDX returned -87.2% over the past year, against +13.5% for the S&P 500.
How many ALDX shares are sold short?
3M shares were sold short at the latest FINRA report, 10.00% of the float, or 3.4 days of average trading volume.
Who are Aldeyra Therapeutics's competitors?
Companies most similar to Aldeyra Therapeutics by business, industry and size include OCUL, HIND, VCNX, KPRX, ELDN.
See a number that looks wrong?